發(fā)布時間：2018-12-14 15:35

【摘要】：肝纖維化是繼發(fā)于各種慢性肝損傷之后組織修復(fù)過程中的代償反應(yīng),其發(fā)病實(shí)質(zhì)是肝內(nèi)細(xì)胞外基質(zhì)(extracellular matrix,ECM)合成與降解動態(tài)平衡發(fā)生紊亂,最終導(dǎo)致ECM過度沉積。肝纖維化的發(fā)生與發(fā)展受到多種細(xì)胞因子及細(xì)胞內(nèi)多種信號轉(zhuǎn)導(dǎo)通路網(wǎng)絡(luò)的調(diào)控,其中很多靶點(diǎn)在肝纖維化中的作用尚沒有完全定論。近年來越來越多的研究證實(shí)細(xì)胞因子信號轉(zhuǎn)導(dǎo)抑制分子-3(suppressor of cytokine signaling,SOCS-3)在肝纖維化的發(fā)生與發(fā)展過程中扮演著重要角色。SOCS-3可通過調(diào)控肝臟內(nèi)炎癥反應(yīng)、細(xì)胞增殖活化、胰島素抵抗、瘦素抵抗等影響肝臟疾病的發(fā)展進(jìn)程。許多學(xué)者認(rèn)為SOCS-3可作為肝纖維化疾病診斷、預(yù)測預(yù)后的生物分子指標(biāo)以及治療靶標(biāo)。該文從SOCS-3系統(tǒng)概述、SOCS-3與肝纖維化關(guān)系、SOCS-3在防治肝纖維化中的作用等方面綜述了SOCS-3在防治肝纖維化中的作用及研究進(jìn)展。
[Abstract]:Liver fibrosis is a compensatory reaction in the process of tissue repair after various chronic liver injury. The essence of hepatic fibrosis is the disorder of the dynamic balance between the synthesis and degradation of extracellular matrix (extracellular matrix,ECM), which leads to the excessive deposition of ECM. The occurrence and development of hepatic fibrosis are regulated by many cytokines and many signal transduction pathway networks in cells, and the role of many targets in liver fibrosis has not been fully concluded. In recent years, more and more studies have confirmed that cytokine signal transduction suppressor molecule-3 (suppressor of cytokine signaling,SOCS-3 plays an important role in the pathogenesis and development of hepatic fibrosis. SOCS-3 can regulate the inflammatory response in the liver. Cell proliferation, insulin resistance and leptin resistance affect the development of liver disease. Many scholars believe that SOCS-3 can be used as a biomolecular index to predict the prognosis of liver fibrosis and as a therapeutic target. This article reviews the role of SOCS-3 in the prevention and treatment of hepatic fibrosis from the aspects of SOCS-3 system, the relationship between SOCS-3 and hepatic fibrosis, and the role of SOCS-3 in the prevention and treatment of hepatic fibrosis.
【作者單位】： 南京中醫(yī)藥大學(xué)藥學(xué)院;南京中醫(yī)藥大學(xué);江蘇省中藥藥效與安全性評價重點(diǎn)實(shí)驗(yàn)室;
【基金】：國家自然科學(xué)基金資助項(xiàng)目(No 81270514,31401210,31571455) 江蘇省自然科學(xué)基金青年基金資助項(xiàng)目(No BK20140955) 江蘇省高校自然科學(xué)研究面上項(xiàng)目資助項(xiàng)目(No 14KJB310011) 江蘇高校優(yōu)勢學(xué)科建設(shè)工程資助項(xiàng)目(No ysxk-2010) 江蘇高校優(yōu)秀科技創(chuàng)新團(tuán)隊(duì)計(jì)劃
【分類號】：R575.2

【參考文獻(xiàn)】

相關(guān)期刊論文 前5條

1 薛博瑜,顧學(xué)蘭;肝纖維化的病機(jī)認(rèn)識和辨證論治[J];南京中醫(yī)藥大學(xué)學(xué)報(自然科學(xué)版);2001年02期

2 張千;鄧存良;;SOCS-3在大鼠慢性肝損傷中的表達(dá)研究[J];四川醫(yī)學(xué);2014年09期

3 張自力;張涉;郭瑤;王妤清;倪雯霞;張衍;孔德松;鄭仕中;;大麻素受體在肝星狀細(xì)胞活化中的作用及姜黃素干預(yù)效應(yīng)[J];中國藥理學(xué)通報;2013年05期

4 張自力;張衍;張涉;段旭酉;郭瑤;倪雯霞;王妤清;鄭仕中;;大麻素受體在肝纖維化及肝硬化中的作用及研究進(jìn)展[J];中國藥理學(xué)通報;2014年03期

5 Kamila Wójcik;Elzbieta Jab，

本文編號：2378880